Ranbaxy will develop an undisclosed biosimilar therapeutic using Pfenex's Pseudomonas-based recombinant protein expression technology. The two companies will develop production strains and the production process for the product.
Business Standard
Thursday, 1 April 2010
Ranbaxy to use Pfenex technology
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment